ClinicalTrials.gg
CompletedNCT01093326Updated Mar 30, 2025Results posted

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

A Phase 2 interventional study of Ponesimod 10 mg and Ponesimod 20 mg in Multiple Sclerosis, sponsored by Actelion. Completed at 72 sites in 20 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
93rd of 879
353 · median 50
Started
2010
with 41 others
Phase 2
139 of 1,192
20 open now
Registered
239th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 93rd largest by enrollment of the 879 interventional ones that give a count, is one of 42 that started in 2010, is one of 139 in phase 2, and was the 239th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who completed study treatment at their regular Week 24 (End of treatment) visit within the core study AC-058B201.
  2. Signed for participating in the extension study.

Exclusion criteria

Exclusion Criteria:

  1. Any medical or surgical condition, which, in the opinion of the investigator, would put the patient at risk by participating in the extension study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Ponesimod 10 mg

    Ponesimod 10 mg oral use

    Drug: Ponesimod 10 mg

  • Experimental
    Ponesimod 20 mg

    Ponesimod 20 mg oral use

    Drug: Ponesimod 20 mg

  • Experimental
    Ponesimod 40 mg

    Ponesimod 40 mg oral use

    Drug: Ponesimod 40 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized Relapse Rate (ARR) of Confirmed Relapses

    ARR is defined as the number of confirmed relapses per year. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previous relapse) of at least 0.5 point in the Expanded Disability Status Scale (EDSS) score, or one point in the score for at least one of the Functional System (FS) scores, excluding the bowel and bladder, and mental FS. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10 (death due to MS).

    Time frame: From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years

  2. Time to First Confirmed Relapse

    Time to first confirmed relapse was reported. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previous relapse) of at least 0.5 point in the Expanded Disability Status Scale (EDSS) score, or one point in the score for at least one of the Functional System (FS) scores, excluding the bowel and bladder, and mental FS. EDSS is ordinal clinical scale ranges from 0 (normal neurological examination) to 10 (death due to MS).

    Time frame: From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years

  3. Time to 24 Weeks Confirmed Disability Progression

    Time to 24 weeks confirmed disability progression (accumulation) was reported. Disability progression is defined as an increase of at least 1 point in the EDSS score if baseline EDSS was between 1 and 5.0, an increase of at least 1.5 points if baseline EDSS was 0, or an increase of at least 0.5 points if the baseline EDSS was equal or greater than 5.5. A 24-week confirmed disability progression is defined as a 24-week sustained increase from baseline in the EDSS scores, that is, every EDSS score (scheduled or unscheduled, with or without relapse) within a 24-week duration after the first progression should meet the progression criteria as specified above. EDSS is ordinal clinical scale ranges from 0 (normal neurological examination) to 10 (death due to MS).

    Time frame: From ponesimod baseline up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years

Other outcomes

  1. Number of Participants With at Least One Treatment-emergent Serious Adverse Events (SAEs)

    Number of participants with at least one treatment-emergent SAEs were reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. Treatment-emergent SAEs were those SAEs that occurred at or after the initial administration of ponesimod up to 15 days (inclusive) after last administration of ponesimod as study drug.

    Time frame: From ponesimod start date up to the end of study treatment + 15 Days. The actual time of observation varied for each participant and could be up to 12.97 years + 15 days

07

Results

Posted Oct 1, 2024

Participant flow

Participants who were enrolled in the core study (NCT01006265) entered this extension study. As planned, combined analysis (core plus extension study) was done for efficacy and safety (435 participants).

Participant flow — Overall Study
MilestonePonesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)
Started115121117
Completed718076
Not completed444141
Withdrew: Death010
Withdrew: Lack of efficacy763
Withdrew: Lost to follow-up254
Withdrew: Physician decision313
Withdrew: Withdrawal by subject302726
Withdrew: Adverse event214
Withdrew: Other001

Outcome measures

PrimaryAnnualized Relapse Rate (ARR) of Confirmed Relapses

ARR is defined as the number of confirmed relapses per year. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previous relapse) of at least 0.5 point in the Expanded Disability Status Scale (EDSS) score, or one point in the score for at least one of the Functional System (FS) scores, excluding the bowel and bladder, and mental FS. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10 (death due to MS).

Time frame:
From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
Reported as:
Mean · Confirmed relapses per year
Annualized Relapse Rate (ARR) of Confirmed Relapses
Confirmed relapses per yearPonesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)
Annualized Relapse Rate (ARR) of Confirmed Relapses0.205 (0.150 to 0.282)0.142 (0.102 to 0.198)0.150 (0.105 to 0.215)
PrimaryTime to First Confirmed Relapse

Time to first confirmed relapse was reported. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previous relapse) of at least 0.5 point in the Expanded Disability Status Scale (EDSS) score, or one point in the score for at least one of the Functional System (FS) scores, excluding the bowel and bladder, and mental FS. EDSS is ordinal clinical scale ranges from 0 (normal neurological examination) to 10 (death due to MS).

Time frame:
From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
Reported as:
Median · Weeks
Time to First Confirmed Relapse
WeeksPonesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)
Time to First Confirmed Relapse272.3 (164.6 to NA)656.7 (278.0 to NA)431.7 (296.3 to NA)
PrimaryTime to 24 Weeks Confirmed Disability Progression

Time to 24 weeks confirmed disability progression (accumulation) was reported. Disability progression is defined as an increase of at least 1 point in the EDSS score if baseline EDSS was between 1 and 5.0, an increase of at least 1.5 points if baseline EDSS was 0, or an increase of at least 0.5 points if the baseline EDSS was equal or greater than 5.5. A 24-week confirmed disability progression is defined as a 24-week sustained increase from baseline in the EDSS scores, that is, every EDSS score (scheduled or unscheduled, with or without relapse) within a 24-week duration after the first progression should meet the progression criteria as specified above. EDSS is ordinal clinical scale ranges from 0 (normal neurological examination) to 10 (death due to MS).

Time frame:
From ponesimod baseline up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
Reported as:
Median · Weeks
Time to 24 Weeks Confirmed Disability Progression
WeeksPonesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)
Time to 24 Weeks Confirmed Disability ProgressionNA (470.3 to NA)NA (NA to NA)NA (NA to NA)
Other pre-specifiedNumber of Participants With at Least One Treatment-emergent Serious Adverse Events (SAEs)

Number of participants with at least one treatment-emergent SAEs were reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. Treatment-emergent SAEs were those SAEs that occurred at or after the initial administration of ponesimod up to 15 days (inclusive) after last administration of ponesimod as study drug.

Time frame:
From ponesimod start date up to the end of study treatment + 15 Days. The actual time of observation varied for each participant and could be up to 12.97 years + 15 days
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsPonesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)
Number of Participants With at Least One Treatment-emergent Serious Adverse Events (SAEs)323525

Adverse events

Collected over For Serious and Non-serious AEs: From ponesimod start date up to end of treatment + 15 days (up to 12.97 years + 15 days); For All-cause Mortality: From ponesimod start date to end of Analysis Period 3 (up to 13.3 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ponesimod 10 Milligrams (mg)0/139 (0%)32/139 (23%)121/139 (87.1%)
Ponesimod 20 Milligrams (mg)1/145 (0.7%)35/145 (24.1%)125/145 (86.2%)
Ponesimod 40 Milligrams (mg)0/151 (0%)25/151 (16.6%)140/151 (92.7%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventPonesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1392/1450/151
Atrioventricular Block Second DegreeCardiac disorders2/1391/1450/151
VertigoEar and labyrinth disorders2/1390/1450/151
Ankle FractureInjury, poisoning and procedural complications2/1390/1450/151
EndometriosisReproductive system and breast disorders2/1390/1451/151
Macular OedemaEye disorders0/1392/1451/151
CholelithiasisHepatobiliary disorders1/1392/1450/151
Road Traffic AccidentInjury, poisoning and procedural complications0/1392/1450/151
Invasive Ductal Breast CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1392/1451/151
Intermenstrual BleedingReproductive system and breast disorders0/1392/1450/151
Most frequent other events
Showing 10 of 61
Most frequent other events
EventPonesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)
NasopharyngitisInfections and infestations46/13946/14545/151
HeadacheNervous system disorders38/13931/14541/151
Upper Respiratory Tract InfectionInfections and infestations27/13928/14539/151
CoughRespiratory, thoracic and mediastinal disorders11/13913/14528/151
Back PainMusculoskeletal and connective tissue disorders21/13923/14522/151
BronchitisInfections and infestations22/13922/14521/151
HypertensionVascular disorders22/13919/14518/151
Urinary Tract InfectionInfections and infestations21/13921/14522/151
ArthralgiaMusculoskeletal and connective tissue disorders21/13916/14516/151
InfluenzaInfections and infestations20/13918/14520/151

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ponesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)Total
<=18 years0000
Between 18 and 65 years115121117353
>=65 years0000
Age, Continuous
Age, Continuous(years)Ponesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)Total
Mean36.6 ± 8.6736.1 ± 8.5835.9 ± 8.6136.2 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Ponesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)Total
Female778076233
Male384141120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ponesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)Total
Hispanic or Latino0022
Not Hispanic or Latino0000
Unknown or Not Reported115121115351
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ponesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)Total
American Indian or Alaska Native0101
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American3249
White112118110340
More than one race0000
Unknown or Not Reported0022
Region of Enrollment
Region of Enrollment(Participants)Ponesimod 10 Milligrams (mg)Ponesimod 20 Milligrams (mg)Ponesimod 40 Milligrams (mg)Total
Austria4228
Bulgaria53513
Canada2226
Czech Republic12171443
Finland66416
France1113
Germany1124
Hungary28515
Israel0213
Italy88622
Netherlands0112
Poland1461131
Romania1203
Russia8111130
Serbia16131140
Spain1449
Sweden46818
Switzerland2103
Ukraine47516
United Kingdom54514
United States19161954
08

Study locations

72 sites
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Palo Alto, California, United States
  • Sacramento, California, United States
  • Venice, Florida, United States
  • Indianapolis, Indiana, United States
  • Kansas City, Kansas, United States
  • Lenexa, Kansas, United States
  • Latham, New York, United States
  • Schenectady, New York, United States
  • Stony Brook, New York, United States
  • Raleigh, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Burlington, Vermont, United States
  • Kirkland, Washington, United States
  • Vienna, Austria
  • Sofia, Bulgaria
  • Ottawa, Ontario, Canada
  • Brno, Czechia
  • Jihlava, Czechia
  • Olomouc, Czechia
  • Ostrava-Poruba, Czechia
  • Praha 2, Czechia
  • Teplice, Czechia
  • Helsinki, Finland
  • Hyvinkää, Finland
  • Tampere, Finland
  • Turku, Finland
  • Montpellier Cedex 5, France
  • Berlin, Germany
  • Essen, Germany
  • Ulm, Germany
  • Budapest, Hungary
  • Esztergom, Hungary
  • Győr, Hungary
  • Miskolc, Hungary
  • Tel-Hashomer, Israel
  • Zerifin, Israel
  • Breda, Netherlands
  • Katowice, Poland
  • Poznan, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Cluj-Napoca, Romania
  • Timisoara, Romania
  • Kazan, Russian Federation
  • Moscow, Russian Federation
  • Nizhniy Novgorod, Russian Federation
  • Pyatigorsk, Russian Federation
  • Saint Petersburg, Russian Federation
  • Samara, Russian Federation
  • Saratov, Russian Federation
  • St. Petersburg, Russian Federation
  • UFA, Russian Federation
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Nis, Serbia
  • Majadahonda, Spain
  • Malaga, Spain
  • Sevilla, Spain
  • Göteborg, Sweden
  • Stockholm, Sweden
  • Umeå, Sweden
  • Lugano, Switzerland
  • Chernihiv, Ukraine
  • Dnipropetrovsk, Ukraine
  • Kyiv, Ukraine
  • Odesa, Ukraine
  • Bristol, United Kingdom
  • London, United Kingdom
  • Plymouth, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Sep 2023, 159 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 159 months is above that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2010
First posted
Mar 25, 2010
StartActual
May 12, 2010
Primary completionActual
Sep 6, 2023
CompletionActual
Sep 6, 2023
Results first posted
Oct 1, 2024
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01093326
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Mar 25, 2010
Start date
May 12, 2010
Primary completion
Sep 6, 2023
Completion
Sep 6, 2023
Results posted
Oct 1, 2024
Last update
Mar 30, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion